Why we invested
At MatchPlay, we invest in companies solving problems that don’t look urgent on the surface but are foundational to everything that follows.
Precision medicine is one of those areas.
AI is expected to unlock breakthroughs in genetic disorders, drug discovery, and personalized care. But there is a more fundamental constraint:
AI in healthcare doesn’t fail because of models. It fails because of data.
The team
Geneial is led by Adam Hansen, whose background spans computational genetics, AI, and large-scale research systems.
What stood out to us was not just technical depth, but clarity of direction. The team understands that the bottleneck in precision medicine is not model capability, but how data is captured, structured, and reused across systems.
That perspective shows up clearly in how Geneial is being built.
Our perspective
Healthcare doesn’t have a data shortage. It has a usable data shortage.
Patient data today is:
- fragmented across institutions and formats
- unstructured and inconsistent
- locked inside systems that don’t communicate
As a result, most datasets cannot be reused, and even advanced AI systems are limited by poor input quality.
The industry has responded by building better analytics and models. But without fixing the underlying data layer, progress remains constrained.
We see this as a foundational infrastructure gap.
What convinced us
Geneial is not building another analytics tool. It is building the data layer that makes analytics possible.
The platform standardizes and structures patient-generated and clinical data across studies, systems, and time, turning fragmented inputs into reusable datasets.
This creates a fundamentally different model:
- data becomes reusable instead of one-time
- studies no longer start from zero
- participation improves as workflows simplify
- insights compound as datasets grow
Incumbents treat data as a byproduct of studies. Geneial treats it as the product.
This is where we see long-term leverage. Every deployment adds structured data to the system, making future studies faster, cheaper, and more valuable. Over time, this creates a compounding network effect that is difficult to replicate.
What reinforced our conviction was early traction — from NIH-backed funding to contracted research revenue and active deployments across global patient communities.
More importantly, the platform is already showing materially higher participation and engagement compared to legacy systems, which directly translates into better data quality.
Why now
The timing is critical.
AI in healthcare is moving from experimentation to application, but the data layer has not kept pace.
At the same time:
- rare disease research is expanding globally
- patient-driven data is becoming central to discovery
- regulators and payers are demanding stronger real-world evidence
This sits within a multi-billion dollar ecosystem spanning registries, real-world data, and biopharma data infrastructure.
As these forces converge, the need for structured, reusable data becomes unavoidable.
Our conviction
We believe platforms that structure and scale healthcare data will become the backbone of precision medicine.
If Geneial succeeds, it won’t just support research. It will define how patient data is captured, structured, and exchanged across the healthcare ecosystem.
Geneial is not just building better data pipelines.
It is building the data layer precision medicine depends on.
